Dr. Lal PathLabs Limited (NSE: LALPATHLAB)

India flag India · Delayed Price · Currency is INR
2,924.15
-22.05 (-0.75%)
Dec 24, 2024, 3:30 PM IST
12.62%
Market Cap 243.62B
Revenue (ttm) 23.46B
Net Income (ttm) 4.01B
Shares Out 83.31M
EPS (ttm) 46.41
PE Ratio 63.01
Forward PE 50.28
Dividend 18.00 (0.61%)
Ex-Dividend Date Nov 5, 2024
Volume 45,992
Open 2,953.75
Previous Close 2,946.20
Day's Range 2,916.00 - 2,959.80
52-Week Range 1,943.70 - 3,653.95
Beta 0.30
Analysts n/a
Price Target n/a
Earnings Date Jan 22, 2025

About Dr. Lal PathLabs

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India. [Read more]

Sector Healthcare
Founded 1949
Employees 4,099
Stock Exchange National Stock Exchange of India
Ticker Symbol LALPATHLAB
Full Company Profile

Financial Performance

In 2023, Dr. Lal PathLabs's revenue was 22.27 billion, an increase of 10.40% compared to the previous year's 20.17 billion. Earnings were 3.58 billion, an increase of 49.78%.

Financial Statements

News

Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls

Shares of Dr Lal Path Labs surged by 3.46%, rising ₹112.75 to trade at ₹3,368.45 on the NSE at 9:16 AM. The stock’s upward movement follows the release of strong Q2 FY25 earnings and positive brokerag...

2 months ago - Business Upturn

Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying

Several brokerages have shared their views on Dr Lal Path Labs. Here’s what they are saying: Goldman Sachs: Goldman Sachs has maintained its sell call on Dr Lal Path and raised the share price target ...

2 months ago - Business Upturn

UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price

UBS has maintained its buy rating on Dr LalPath Labs, with a share price target of ₹3,500, indicating a 7.7% upside from the current market price (CMP). The company’s Q2 performance was robust, showin...

2 months ago - Business Upturn

Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore

Dr Lal PathLabs has reported solid financial results for Q2 FY25, showing notable growth in both revenue and net profit on a year-on-year (YoY) basis. Key Financial Highlights: Revenue for Q2 FY25 sto...

2 months ago - Business Upturn

Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720

Nomura has maintained its ‘Buy’ rating on Dr Lal PathLabs, setting a target price of ₹3,720, which implies a potential upside from the current market price of ₹3,280. Nomura expects steady performance...

2 months ago - Business Upturn